Mathematical modeling of postcoinfection with influenza A virus and Streptococcus pneumoniae, with implications for pneumonia and COPD-risk assessment

International Journal of COPD

Volumn 12, Issue , 2017, Pages 1973-1988

  Cheng, Yi Hsien ^a   You, Shu Han ^b   Lin, Yi Jun ^c   Chen, Szu Chieh ^d   Chen, Wei Yu ^e   Chou, Wei Chun ^b   Hsieh, Nan Hung ^f   Liao, Chung Min ^c  

^a KANSAS STATE UNIVERSITY   (United States)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^f TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Chronic obstructive pulmonary disease; Coinfection; Influenza; Modeling; Pneumonia; Risk assessment

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL LOAD; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION RISK; INFLAMMATION; INFLUENZA; INFLUENZA A VIRUS; MATHEMATICAL MODEL; MIXED INFECTION; MOUSE; NONHUMAN; PNEUMOCOCCAL INFECTION; PNEUMONIA; RISK ASSESSMENT; SECONDARY INFECTION; STREPTOCOCCUS PNEUMONIAE; VIRUS TITRATION; ANIMAL; COMPUTER SIMULATION; DISEASE MODEL; MICROBIOLOGY; MONTE CARLO METHOD; PATHOGENICITY; RISK FACTOR; THEORETICAL MODEL; TIME FACTOR; TRANSMISSION; VIROLOGY;

ANIMALS; COINFECTION; COMPUTER SIMULATION; DISEASE MODELS, ANIMAL; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MICE; MODELS, THEORETICAL; MONTE CARLO METHOD; PNEUMOCOCCAL INFECTIONS; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS;

EID: 85023604096     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S138295     Document Type: Article

References (41)

1. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev. 2006;19:571-582.
2. McCullers JA. The co-pathogenesis of influenza viruses with bacteria in the lung. Nat Rev Microbiol. 2014;12:252-262.
3. Blyth CC, Webb SA, Kok J, et al. The impact of bacterial and viral co-infection in severe influenza. Influenza Other Respir Viruses. 2013;7:168-176.
4. Bosch AA, Biesbroek G, Trzcinski K, Sanders EA, Bogaert D. Viral and bacterial interactions in the upper respiratory tract. PLoS Pathog. 2013;9:e1003057.
5. Chertow DS, Memoli MJ. Bacterial coinfection in influenza: a grand rounds review. JAMA. 2013;309:275-282.
6. Kosai K, Seki M, Tanaka A, et al. Increase of apoptosis in a murine model for severe pneumococcal pneumonia during influenza A virus infection. Jpn J Infect Dis. 2011;64:451-457.
7. Weinberger DM, Simonsen L, Jordan R, Steiner C, Miller M, Viboud C. Impact of the 2009 influenza pandemic on pneumococcal pneumonia hospitalizations in the United States. J Infect Dis. 2012;205:458-465.
8. World Health Organization. The top 10 causes of death. 2017. Available from: http://www.who.int/mediacentre/factsheets/fs310/en. Accessed June 12, 2017.
9. McNamee LA, Harmsen AG. Both influenza-induced neutrophil dysfunction and neutrophil-independent mechanisms contribute to increased susceptibility to a secondary Streptococcus pneumoniae infection. Infect Immun. 2006;74:6707-6721.
10. Shahangian A, Chow EK, Tian X, et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest. 2009;119:1910-1920.
11. Sun K, Metzger DW. Inhibition of pulmonary antibacterial defense by interferon-γ during recovery from influenza infection. Nat Med. 2008;14:558-564.
12. Raza SL, Cornelius LA. Matrix metalloproteinases: pro-and anti-angiogenic activities. J Investig Dermatol Symp Proc. 2000;5:47-54.
13. van der Sluijs KF, van Elden LJ, Nijhuis M, et al. IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J Immunol. 2004;172:7603-7609.
14. Tashiro M, Ciborowski P, Klenk HD, Pulverer G, Rott R. Role of Staphylococcus protease in the development of influenza pneumonia. Nature. 1987;325:536-537.
15. Smith AM, Adler FR, Ribeiro RM, et al. Kinetics of coinfection with influenza A virus and Streptococcus pneumoniae. PLoS Pathog. 2013;9:e1003238.
16. Shrestha S, Foxman B, Weinberger DM, Steiner C, Viboud C, Rohani P. Identifying the interaction between influenza and pneumococcal pneumonia using incidence data. Sci Transl Med. 2013;5:191ra84.
17. Shrestha S, Foxman B, Dawid S, et al. Time and dose-dependent risk of pneumococcal pneumonia following influenza: a model for within-host interaction between influenza and Streptococcus pneumoniae. J R Soc Interface. 2013;10:20130233.
18. Smith AM, McCullers JA, Adler FR. Mathematical model of a three-stage innate immune response to a pneumococcal lung infection. J Theor Biol. 2011;276:106-116.
19. Bautista-Márquez A, Richardson V, Ortiz-Orozco O, et al. Prevalence of pneumococcal disease, serotype distribution, and antimicrobial susceptibility in Mexican children younger than 5 years of age. Arch Med Res. 2013;44:142-150.
20. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22:659-661.
21. Keeling MJ, Rohani P. Modeling Infectious Diseases in Humans and Animals. Princeton, NJ: Princeton University Press; 2008.
22. Cauley LS, Vella AT. Why is coinfection with influenza virus and bacteria so difficult to control? Discov Med. 2015;19:33-40.
23. Onishi M, Kitano M, Taniguchi K, et al. Intravenous peramivir inhibits viral replication, and leads to bacterial clearance and prevention of mortality during murine bacterial co-infection caused by influenza A(H1N1)pdm09 virus and Streptococcus pneumoniae. Antiviral Res. 2015;117:52-59.
24. Li W, Moltedo B, Moran TM. Type I interferon induction during influenza virus infection increases susceptibility to secondary Streptococcus pneumoniae infection by negative regulation of γδ T cells. J Virol. 2012;86:12304-12312.
25. Endeman H, Meijvis SC, Rijkers GT, et al. Systemic cytokine response in patients with community-acquired pneumonia. Eur Respir J. 2011;37:1431-1438.
26. Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE. Local and systemic cytokine responses during experimental human influenza A virus infection: relation to symptom formation and host defense. J Clin Invest. 1998;101:643-649.
27. Kragsbjerg P, Holmberg H, Vikerfors T. Dynamics of blood cytokine concentrations in patients with bacteremic infections. Scand J Infect Dis. 1996;28:391-398.
28. Mehta D, Petes C, Gee K, Basta S. The role of virus infection in deregulating the cytokine response to secondary bacterial infection. J Interferon Cytokine Res. 2015;35:925-934.
29. Shi X, Zhou W, Huang H, et al. Inhibition of the inflammatory cytokine tumor necrosis factor-alpha with etanercept provides protection against lethal H1N1 influenza infection in mice. Crit Care. 2013;17:R301.
30. Lee N, Wong CK, Chan PK, et al. Cytokine response patterns in severe pandemic 2009 H1N1 and seasonal influenza among hospitalized adults. PLoS One. 2011;6:e26050.
31. Canini L, Carrat F. Population modeling of influenza A/H1N1 virus kinetics and symptom dynamics. J Virol. 2011;85:2764-2770.
32. Kaiser L, Fritz RS, Straus SE, Gubareva L, Hayden FG. Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses. J Med Virol. 2001;64:262-268.
33. Pichlmair A, Sousa CR. Innate recognition of viruses. Immunity. 2007;27:370-383.
34. Kash JC, Walters KA, Davis AS, et al. Lethal synergism of 2009 pandemic H1N1 influenza virus and Streptococcus pneumoniae coinfection is associated with loss of murine lung repair responses. MBio. 2011;2:e00172.
35. Wu DB, Chong HY, Lee KK. Cost-effectiveness analysis of joint vaccination with 13-valent pneumococcal conjugate vaccine (Pcv13) and influenza vaccine in Taiwan during seasonal influenza. Value Health. 2014;17:A273.
36. Katsura H, Piao Z, Iwatsuki-Horimoto K, et al. A bivalent vaccine based on a replication-incompetent influenza virus protects against Streptococcus pneumoniae and influenza virus inflection. J Virol. 2014;88:13410-13417.
37. Albrich WC, Monnet DL, Harbarth S. Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes. Emerg Infect Dis. 2004;10:514-517.
38. Sethi S, Sethi R, Eschberger K, et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176:356-361.
39. Papi A, Bellattato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173:1114-1121.
40. Mallia P, Johnston SL. Influenza infection and COPD. Int J Chron Obstruct Pulmon Dis. 2007;2:55-64.
41. Chen SC, You SH, Liu CY, Chio CP, Liao CM. Using the experimental human influenza infections to validate a viral dynamic model and the implications for prediction. Epidemiol Infect. 2012;140:1557-1568.